41 research outputs found
Predictive factors for the efficacy of Er:YAG laser treatment of urinary incontinence
Objectives: To determine the efficacy and predictive factors for the success of Er:YAG laser treatment in patients with urinary incontinence (UI)
Tibolone and breast cancer
Tibolone is a relatively new drug for postmenopausal women, which is structurally related to 19-nortestosterone derivatives and exhibits weak oestrogenic, progestogenic and androgenic activities. The effect of tibolone on breast tissue is still obscure. In vitro studies have shown conflicting results regarding the effects of tibolone on breast cells. On the other hand, although epidemiological studies show an increase in the risk of breast cancer among women treated with tibolone, accumulation of data obtained from radiological studies presents promising results. However, the safety of tibolone with regard to breast tissue needs to be investigated further, especially through well- designed, large-scale, randomised-controlled trials
Er:YAG laser treatment of urinary incontinence after failed TOT/TVT procedures
Objective: To determine if the Er:YAG laser can improve the symptoms of SUI patients after previously failed TOT/TVT procedures
Diagnosis of late-onset congenital adrenal hyperplasia in clinical practice: current evaluation
Aim. Aim of the study was to investigate the need to perform the adrenocorticotropic hormone (ACTH) stimulation test by recognizing the importance of a second look at basal serum 17-alpha hydroxyprogesterone (17-OHP) levels and calculating new serum 17-OHP cut-off level
Should estrogen be used in the co-treatment of COVID-19 patients? What is the rationale?
Effect of different hormonal therapies on thyroid function in surgical menopause - Short-term results
To determine the effects of different hormone replacement therapy (HRT) regimens on thyroid function in surgical menopause. STUDY DESIGN: In a randomized, controlled study, 59 euthyroid women with surgical menopause were randomized to an estrogenonly (n=20), tibolone (n=20) or calcium-only (n = 19) group. On the 5th postoperative day and 4th and 12th weeks, serum E-2, TSH, free T3 and free T4 levels were determined. RESULTS: Although the initial and week 4 serum E-2, TSH, free T3 and free T4 levels were comparable, the week 12 serum E-2 and TSH levels were different between the subjects on estrogen therapy and those receiving tibolone or calcium only (p = 0.008 and 0.000, respectively). Serum E-2 levels were higher and TSH levels lower in subjects receiving estrogen. Moreover, serum TSH levels correlated negatively with serum E-2 levels in the 12th week of estrogen use (r = -0.354, p = 0.006). TSH increased in the tibolone group as compared to the estrogen group but was still lower than in the calcium-only group; however, the differences were not statistically significant. CONCLUSION: Irrespective of different regimens, HRT does not have an important short-term effect on thyroid function in women with surgical menopause
EMAS position statement: managing the menopause in women with epilepsy.
Epilepsy is a major public health problem worldwide which is clinically characterized by recurrent seizures.Consensus Development ConferenceJournal ArticleReviewinfo:eu-repo/semantics/publishe
EMAS position statement: managing obese postmenopausal women.
Obesity is a public health problem, with overweight individuals representing approximately 20% of the adult world population. Postmenopausal status is associated with higher prevalence of obesity, as 44% of postmenopausal women are overweight, among whom 23% are obese. Obesity often co-exists with other diseases, the most important being diabetes mellitus, dyslipidemia and hypertension. Furthermore, obesity increases the risk of gynecologic cancer, cardiovascular disease, venous thromboembolism, osteoarthritis and chronic back pain.Consensus Development ConferenceJournal Articleinfo:eu-repo/semantics/publishe